SCYNEXIS Offers Data Showing Support for Activity of SCY-078 Against Antifungal-Resistant Candida Strains

Drug development company SCYNEXIS, Inc. (Nasdaq: SCYX) announced today that results of three nonclinical studies of the company's lead ...